Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BONIVA vs ATELVIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bisphosphonate that inhibits bone resorption via binding to hydroxyapatite and inhibiting osteoclast activity.
Risedronate (the active ingredient in ATELVIA) inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting the mevalonate pathway, which prevents farnesyl pyrophosphate synthase activity, leading to disruption of osteoclast function and induction of apoptosis.
Treatment and prevention of postmenopausal osteoporosis,Treatment of glucocorticoid-induced osteoporosis
Treatment of osteoporosis in postmenopausal women,Treatment of osteoporosis in men at high risk of fracture,Treatment and prevention of glucocorticoid-induced osteoporosis,Off-label: Paget's disease of bone
150 mg orally once monthly; 2.5 mg orally once daily also approved but less commonly used. Administer on empty stomach with plain water (6-8 oz) at least 60 minutes before first food, beverage, or other medications. Do not lie down for 60 minutes after administration.
35 mg orally once weekly on the same day each week, taken with at least 240 m L of plain water at least 30 minutes before the first food, beverage, or medication of the day. Do not crush, chew, or suck tablets.
Terminal half-life: 10-60 hours (clinical relevant); long terminal half-life (120-720 hours) due to slow dissociation from bone, supports weekly dosing.
Terminal elimination half-life is approximately 10 days due to prolonged bone binding and slow release; clinical suppression of bone resorption persists for weeks after discontinuation.
Not metabolized; excreted unchanged by the kidneys.
Risedronate is not metabolized and is excreted unchanged primarily by the kidneys (<5% metabolized). No cytochrome P450 enzymes involved.
Renal: ~50-60% unchanged in urine; biliary/fecal: ~40-50% eliminated via feces, primarily as unchanged drug.
Approximately 50% of absorbed dose excreted renally unchanged; remainder eliminated via biliary/fecal routes. Renal clearance correlates with creatinine clearance.
~85-90% bound to plasma proteins, primarily albumin.
Approximately 99% bound to plasma proteins, primarily albumin.
Vd: 0.9-1.3 L/kg, indicating extensive distribution into bone and soft tissues.
Mean Vd is 6.2 L/kg (range 4-10 L/kg), indicating extensive distribution into bone and soft tissues.
Oral: 0.63% (fasting state); reduced to ~0.4% with food.
Oral bioavailability is approximately 0.7% (range 0.5-1.0%) under fasting conditions; food and calcium-containing beverages significantly reduce absorption.
Contraindicated if Cr Cl < 30 m L/min. No adjustment for Cr Cl ≥ 30 m L/min. For Cr Cl 30-49 m L/min: avoid use due to lack of data; per FDA labeling, not recommended. For severe renal impairment (Cr Cl < 30): do not use.
Contraindicated in patients with Cr Cl <15 m L/min. No dose adjustment required for Cr Cl ≥15 m L/min. For Cr Cl 15-30 m L/min, use with caution due to limited data.
No specific adjustment required for hepatic impairment. Drug is not extensively metabolized by liver; pharmacokinetics unchanged in mild-to-moderate hepatic impairment. No data for severe hepatic impairment.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use caution.
Not approved for pediatric use. Safety and efficacy in patients < 18 years have not been established.
Not approved for use in pediatric patients; safety and efficacy not established in children.
No dose adjustment necessary based on age alone. Monitor renal function (Cr Cl) as elderly more likely to have decreased renal function; contraindicated if Cr Cl < 30 m L/min. Ensure adequate calcium and vitamin D intake.
No specific dose adjustment required. Consider potential renal impairment (assess Cr Cl) and increased risk of gastrointestinal adverse effects. Ensure adequate calcium and vitamin D intake.
None.
No FDA black box warning.
Hypocalcemia must be corrected before therapy,Renal impairment: not recommended if Cr Cl <30 m L/min,Osteonecrosis of the jaw (ONJ),Atypical femur fractures,Severe musculoskeletal pain
Hypocalcemia must be corrected before therapy initiation,Severe renal impairment (Cr Cl <30 m L/min): not recommended,Osteonecrosis of the jaw (ONJ) with invasive dental procedures,Atypical femur fractures with long-term use,Upper gastrointestinal adverse events (e.g., esophagitis, ulcers) if taken incorrectly,Hypersensitivity reactions including angioedema
Hypersensitivity to ibandronate or any component,Hypocalcemia,Inability to stand or sit upright for at least 60 minutes
Hypocalcemia,Creatinine clearance <30 m L/min,Inability to stand or sit upright for at least 30 minutes,History of esophageal disorders (e.g., stricture, achalasia)
Food, beverages other than plain water, and medications significantly reduce absorption. Avoid all food, drink, and oral medications for at least 60 minutes after dose. For patient convenience, consider once-monthly dosing on the same day each month. Antacids, calcium or iron supplements, and mineral waters should be taken at least 60 minutes after BONIVA.
Food, beverages (except plain water), and calcium supplements reduce absorption. Avoid any food or drink for at least 30 minutes after dosing. Do not take with mineral water, coffee, tea, juice, or dairy products. Calcium, iron, magnesium, or aluminum-containing antacids should be taken at a different time of day.
FDA Pregnancy Category C. In pregnant rats, intravenous ibandronate at doses ≥1 mg/kg/day caused fetal skeletal malformations, especially in the skull. In rabbits, no malformations at oral doses up to 10 mg/kg/day but maternal toxicity and reduced fetal weight occurred. Human data: insufficient. Theoretical risk of fetal skeletal abnormalities if used in pregnancy. Avoid use during pregnancy, especially in the second and third trimesters due to potential bone development interference.
Category C: In animal studies, bisphosphonates cause fetal skeletal abnormalities at high doses. During first trimester, theoretical risk of skeletal formation interference. Second/third trimester: Potential for maternal hypocalcemia affecting fetal bone development. No adequate human studies. Risk cannot be excluded.
Ibandronate is excreted in rat milk at concentrations 0.9 times maternal plasma levels. Human data: unknown. Risk to infant: potential for hypocalcemia and gastrointestinal irritation. Use during breastfeeding only if clearly needed and consider monitoring infant serum calcium. M/P ratio: not established in humans.
Unknown: Excretion in human milk is unknown but likely low due to high protein binding and short half-life. M/P ratio not established. Use with caution in breastfeeding due to potential for bone growth suppression in infants; alternatives preferred.
Pharmacokinetic changes in pregnancy (e.g., increased renal clearance, expanded plasma volume) may reduce ibandronate exposure, but no established dose adjustment. Due to teratogenicity and lack of data, avoid use during pregnancy. If inadvertently used, no specific dose adjustment is recommended; however, monitor for hypocalcemia and consider discontinuation. No dosage adjustment postpartum is required.
No formal dose adjustments studied. Pregnancy may increase bone turnover and renal clearance, but data insufficient to recommend dose change. Use lowest effective dose only if clearly needed. Avoid during pregnancy unless benefit outweighs risk.
Administer on an empty stomach, first thing in the morning, with a full glass of plain water (6-8 oz). Patient must remain upright for at least 60 minutes after dosing to reduce esophageal irritation. Monitor serum calcium, phosphate, and vitamin D levels prior to initiation and periodically. Contraindicated in severe renal impairment (Cr Cl <30 m L/min). Discontinue if severe musculoskeletal pain occurs.
ATELVIA (risedronate) is a bisphosphonate for osteoporosis. Must be taken on an empty stomach with plain water only, at least 30 minutes before first food, drink, or other medication. Avoid in severe renal impairment (Cr Cl <30 m L/min). Monitor for hypocalcemia before initiation. Advise patients to remain upright for 30 minutes post-dose to reduce esophageal irritation.
Take tablet immediately after waking up with a full glass of plain water, at least 60 minutes before any food, drink, or other medications.,Do not chew, suck, or crush the tablet; swallow it whole.,Stay upright (sitting or standing) for at least 60 minutes after taking the tablet to prevent esophageal irritation.,If you miss a dose, skip it and resume the next morning; do not take two doses on the same day.,Ensure adequate intake of calcium and vitamin D as directed by your physician.,Report sudden thigh or groin pain, or jaw pain with loose teeth, as these may indicate rare adverse effects.
Take ATELVIA first thing in the morning, at least 30 minutes before any food, drink, or other medications.,Swallow the tablet whole with a full glass (6-8 oz) of plain water only; do not use mineral water, coffee, tea, or juice.,Do not chew, crush, or suck the tablet; remain upright (sitting or standing) for at least 30 minutes after taking.,If you miss a dose, skip it and take the next dose the following morning; do not take two doses on the same day.,Report symptoms of esophageal irritation such as difficulty or pain with swallowing, chest pain, or heartburn.,Ensure adequate intake of calcium and vitamin D as directed by your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BONIVA vs ATELVIA, answered by our medical review team.
BONIVA is a Bisphosphonate that works by Bisphosphonate that inhibits bone resorption via binding to hydroxyapatite and inhibiting osteoclast activity.. ATELVIA is a Bisphosphonate that works by Risedronate (the active ingredient in ATELVIA) inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting the mevalonate pathway, which prevents farnesyl pyrophosphate synthase activity, leading to disruption of osteoclast function and induction of apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BONIVA and ATELVIA depend on the specific clinical indication. These are both Bisphosphonate agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BONIVA is: 150 mg orally once monthly; 2.5 mg orally once daily also approved but less commonly used. Administer on empty stomach with plain water (6-8 oz) at least 60 minutes before first food, beverage, or other medications. Do not lie down for 60 minutes after administration.. The standard adult dose of ATELVIA is: 35 mg orally once weekly on the same day each week, taken with at least 240 m L of plain water at least 30 minutes before the first food, beverage, or medication of the day. Do not crush, chew, or suck tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BONIVA and ATELVIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BONIVA is classified as Category C. FDA Pregnancy Category C. In pregnant rats, intravenous ibandronate at doses ≥1 mg/kg/day caused fetal skeletal malformations, especially in the skull. In rabbits, no malformations. ATELVIA is classified as Category C. Category C: In animal studies, bisphosphonates cause fetal skeletal abnormalities at high doses. During first trimester, theoretical risk of skeletal formation interference. Second. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.